Home >  Medicine MDTV >  Medicine Shorts >  Researchers Highlight RSV...

Researchers Highlight RSV Vaccine Less Effective for Immunocompromised People

By - Dr. Bhumika Maikhuri
Published On 2025-01-01 03:00 GMT   |   Update On 2025-01-01 03:00 GMT
Advertisement
Johns Hpkins Medicine researchers have shown that people 60 years or older with weakened immunity, primarily organ transplant recipients who take immunosuppressive medications do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with normal immune function. The study was published in theJournal of the American Medical Association (JAMA
).
The researchers used an ongoing, Johns Hopkins Medicine-led national study — the Emerging Pathogens of Concern in Immunocompromised Persons (EPOC) — to follow 38 people (between ages 64 and 72) who self-reported that they are immunocompromised and received either the RSVPreF3-AS01 (also known as Arexvy) or RSVpreF (also known as Abrysvo) vaccine. The study group was evenly split between males and females, with 82% being solid organ transplant recipients and 74% taking two or more immunosuppressive medications.
Advertisement
The two vaccines induce the immune system to target a critical protein on the surface of RSV, the F protein, in its pre-infection form, known as pre-fusion F. High levels of antibodies against pre-fusion F, particularly those that neutralize and block RSV from entering cells, are a major contributor in preventing RSV infections. Although most people are infected by RSV many times in their lives, natural infections do not lead to a sufficient level of virus-neutralizing, anti-pre-fusion F antibodies to prevent reinfections, and perhaps, prevent serious illness.
Arexvy contains an adjuvant while Abrysvo does not.
“When we compared the antibody responses between those study participants who received Arexvy with those who got Abrysvo, we found that the group receiving the adjuvanted vaccine tended to have higher levels of RSV-neutralizing, anti-pre-fusion F antibodies,” says study senior author William Werbel, M.D., Ph.D., assistant professor of medicine at the Johns Hopkins University School of Medicine. “So, adjuvant-enhanced vaccines as a means of improving immune response in people who are immunocompromised merits further investigation in larger, more comprehensive studies.”
However, researchers point out that this study does not suggest RSV vaccines will not reduce RSV disease in people who are immunocompromised.
Reference: https://www.newswise.com/articles/people-who-are-immunocompromised-may-not-produce-enough-protective-antibodies-against-rsv-after-vaccination
Full View
Tags:    
Article Source : Journal of the American Medical Association (JAMA)

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Bhumika Maikhuri

Dr Bhumika Maikhuri is an orthodontist with 2 years of clinical experience. She is also working as a medical writer and anchor at Medical Dialogues. She has completed her BDS from Dr D.Y. Patil Medical College and Hospital and MDS from Kalinga Institute of Dental Sciences. She has a few publications and patents to her credit. Her diverse background in clinical dentistry and academic research uniquely positions her to contribute meaningfully to our team.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Real-World Case: Managing Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Akhil Kapoor

Cochrane Review Raises Concerns Over Off-Label Use of Ketamine for Chronic Pain

American Geriatrics Society Releases Updated Guidelines for Safer Medication Use in Older Adults

Study Reveals-Weekend Habits Linked to Spike in Sleep Apnoea Severity

The Prediabetes Show - Episode 2: Catching It Before Progression-A Window of Opportunity?

PCV20 Launch in India: A Single Dose, Science-Driven Approach for Pneumococcal Disease Control

Updated Clinical Guidelines on Pharmacotherapy for Obesity Management: CMAJ

WHO Advises Against Routine Antibiotic Use in COVID-19 Cases Without Bacterial Infection